Chronic graft-versus-host disease after reduced-intensity stem cell transplantation versus conventional hematopoietic stem cell transplantation

Hematology

Volumn 10, Issue 1, 2005, Pages 1-10

  Busca, Alessandro ^a   Rendine, Sabina ^a   Locatelli, Franco ^a   Sizzano, Federico ^a   Dall'omo, Anna Maria ^a   Rossi, Giuseppe ^b   Falda, Michelle ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Chronic graft versus host disease; Conventional stem cell transplantation; Immunosuppressive treatment; Reduced intensity stem cell transplantation

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ARTIFICIAL TEAR; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID; PENTAMIDINE; PREDNISONE; SUNSCREEN; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION COMPLICATION; INFECTION PREVENTION; KAPLAN MEIER METHOD; MALE; MOUTHWASH; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDY; SKIN DISEASE;

ADULT; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN DISEASES; TRANSPLANTATION CONDITIONING;

EID: 23244467317     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330400026188     Document Type: Article

References (30)

1. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analogue-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
2. Khouri I, Keating M, Korbling M. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.
3. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic disease. Blood 1998;91:756-763.
4. Bornhauser M, Thiede C, Schuler U, et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000;26:119-124.
5. Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003;102:470-476.
6. Mineishi S, Kanda Y, Saito T, et al. Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. Br J Haematol 2003;121:296-303.
7. Levine JE, Uberti JP, Ayash L, et al. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 2003;9:189-197.
8. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-762.
9. Nakai K, Mineishi S, Kami M, et al. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation 2003;75:21-35.
10. Schulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: A long-term clinicopathological study of 20 Seattle patients. Am J Med 1980;69:204-217.
11. Sullivan Km. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED, editors. Hematopoietic cell transplantation. Cambridge, MA: Blackwell Scientific Publications; 1999. p 515-536.
12. Lee SJ, Vogelsang G, Flowers ME. Chronic graft versus host disease. Biol Blood Marrow Transplant 2003;9:215-233.
13. Sutherland HJ, Fyles GM, Adams G, et al. Quality of life following bone marrow transplantation: A comparison of patient report with population norms. Bone Marrow Transplant 1997;19:1129-1136.
14. Duell T, Van Lint MT, Ljungman P, et al. Health and functional status of long-term survivors of bone marrow transplantation: EBMT Working Party on late effects and EULEP Study Group on late effects: European group for blood and marrow transplantation. Ann Intern Med 1997;126:184-192.
15. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989;74:1428-1435.
16. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999;341:14-21.
17. Flowers MED, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term follow-up of a randomized trial. Blood 2002;100:415-419.
18. Anderson D, DeFor T, Burns L, et al. A comparison of related donor peripheral blood and bone marrow transplants: Importance of late-onset chronic graft-versus-host disease and infections. Biol Blood and Marrow Transplant 2003;9:52-59.
19. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A meta-analysis. J Clin Oncol 2001;19:3685-3691.
20. Nash RA, Johnston L, Parker PM, et al. A phase I/II study of mycophenolate mofetil (MMF) in combination with cyclosporine (CSP) for prophylaxis of graft versus host disease (GVHD) after myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT): Dose escalation of MMF. Blood 2003;102:240a.
21. Bolwell BJ, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine + short course methotrexate to cyclosporine + mycophenolate for GVHD prophylaxis in ablative allogeneic BMT. Blood 2003;102:711a.
22. Colson YL, Lange J, Fowler K, Lidstad ST. Mechanism for cotolerance in nonlethally conditioned mixed chimeras: Negative selection of the Vβ T-cell receptor repertoire by both host and donor bone marrow-derived cells. Blood 1996;88:4601-4610.
23. Ordemann R, Hutchinson R, Friedman J, et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest 2002;109:1249-1256.
24. Hill GR, Crawford JM, Cooke F R, et al. Total body irradiation and acute graft-versus-host disease: The role of grastrointestinal damage and inflammatory cytokines. Blood 1997;90:3204-3213.
25. Hill GR, Teshima T, Gerbita A, et al. Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft-versus leukaemia. J Clin Invest 1999;104:459-462.
26. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease does not require alloantigen expression on host epithelium. Nat Med 2002;8:575-581.
27. Chan GW, Gorgun G, Miller KB, et al. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease, Biol Blood and Marrow Transplant 2003;9:170-176.
28. Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood and Marrow Transplant 2004;10:178-185.
29. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2002;96:2419-2425.
30. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haematopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 2004;33:691-696.